Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients.

ABSTRACT:

Background

This real-life study aimed to assess omalizumab treatment patterns in adult and paediatric asthma patients, and to describe asthma control and healthcare resource use (HCRU) at omalizumab initiation and discontinuation.

Methods

The French healthcare database system (Système National des Données de Santé (SNDS)) was used to identify asthma patients aged ≥6 years who initiated omalizumab for at least 16 weeks from 2009 to 2019. We examined omalizumab treatment patterns using dispensation records.

Results

We identified 16 750 adults and 2453 children initiating omalizumab. Median treatment persistence before discontinuation (T_STOP) was 51.2 (95% CI 49.3-53.4) months in adults and 53.7 (95% CI 50.6-56.4) months in children. At 2 years of omalizumab e

SUBMITTER: Humbert M 

PROVIDER: S-EPMC9647070 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature